However, the effect of rifampin on atorvastatin concentrations in hepatocytes is unknown and if the simultaneous use can not be avoided, it is necessary to carefully monitor the effectiveness of such therapy.
Kodwa-ke, umphumela we-rifampicin ekuhlakazweni kwe-atorvastatin kumaseli wesibindi awaziwa, futhi uma kungenakwenzeka ukugwema ukusetshenziswa ngasikhathi sinye, ukusebenza ngempumelelo kwesiguli kufanele kugadwe ngokucophelela.